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Introduction. In medically refractory Parkinson’s disease (PD) deep-brain stimulation (DBS) is an effective therapeutic tool.
Postimplantation MRI is important in assessing tissue damage and DBS lead placement accuracy. We wanted to identify which
MRI sequence can detect DBS leads with smallest artifactual signal void, allowing better tissue/electrode edge conspicuity.Methods.
Using an IRB approved protocol 8 advancedPDpatientswere imagedwithinMRconditional safety guidelines at lowRFpower (SAR
≤ 0.1W/kg) in coronal plane at 1.5T by various sequences. The image slices were subjectively evaluated for diagnostic quality and
the lead contact diameters were compared to identify a sequence least affected by metallic leads. Results and Discussion. Spin echo
and fast spin echo based low SAR sequences provided acceptable image quality with comparable image blooming (enlargement)
of stimulator leads. The mean lead diameters were 2.2 ± 0.1mm for 2D, 2.1 ± 0.1mm for 3D, and 4.0 ± 0.2mm for 3D MPRAGE
sequence. Conclusion. Low RF power spin echo and fast spin echo based 2D and 3D FSE sequences provide acceptable image
quality adjacent to DBS leads. The smallest artifactual blooming of stimulator leads is present on 3D FSE while the largest signal
void appears in the 3D MPRAGE sequence.
1. Introduction
Inmedically refractory Parkinson’s disease, deep brain stimu-
lation (DBS) is often an effective therapeutic tool as noted by
Obeso et al. [1] acting on the cells and fibers located closest
to the implanted electrode. However, it remains unclear
exactly how DBS therapy improves symptoms in Parkinson’s
patients, and the benefits of DBS are currently understood
only empirically Okun [2]. Around the lead track, a thin
capsule of connective tissue (thickness 5 to 25𝜇m) is formed
surrounded by a 500 𝜇m or less rim of fibrillary gliosis as
noted by Haberler et al. [3] after postmortem examination.
In the adjacent brain tissue of thickness less than 1mm,
loosely scattered glial fibrillary acidic protein-positive protein
astrocytes are found and stimulation seems to modify the
tissue microstructure of the local encapsulation, increas-
ing conductivity and decreasing electrode impedance. It is
important to directly visualize or indirectly estimate the size
and relative contrast of surrounding tissue, preferably by
MRI.
The goals of this study were twofold: first we wanted
to see if MRI detectable leads have large size difference for
patients immediately after implantation with no observable
complications, and, second, we sought to explore if there
are MR sequence specific size differences in visualized signal
voids for DBS leads. The role of MRI for assessing DBS lead
placement accuracy has already demonstrated [4] significant
advantages despite ignoring the lead-tissue interface.
DBS leads are built with conducting metals (Pt/Ir alloy)
that are mildly paramagnetic and produce artifactual signal
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loss in vivo for all MRI sequences. We asked the questions:
what the limit of edge detection and localizability of DBS
leads is, and which sequence minimizes the blooming arti-
facts. In other words, it is important to improve visualization
of tissue edges adjacent to implant tips and minimize tissue
signal loss due to high susceptibility of metallic components
in the implanted electrodes.
During an MRI the DBS electrodes deposit a significant
amount of radiofrequency induced heat due to the metallic
composition (represented by specific absorption rate, SAR)
to the surrounding tissue as described by Zrinzo et al. [5]
and Tagliati et al. [6]. Hence the DBS vendor Medtronic Inc.
and the FDA have provided MR conditional guidance [7, 8]
for imaging hardware and a maximum SAR level allowed for
imaging of patients with DBS.The present work has followed
these restrictions during the development and testing phases
on non-DBS subjects and the results have been reported
elsewhere by Sarkar et al. [9].
2. Materials and Methods
2.1. Patient Selection. Following institutional ethics and
research review committee guidelines at our institution,
eight patients with advanced Parkinson’s disease that were
refractory to medications were studied after implantation of
DBS for lead localization (4 males, 4 females, age range 53–
75 years, disease duration 8–16 years, median 11.5 years, and
UPDRS score:more than 30withoutmedication;medical his-
tory included dyskinesia, speech and/or memory difficulty,
depression, and gait disorder).
2.2. Imaging Details. MR sequences used were 2D fast spin
echo T2 (FSE T2) for 4 patients, 3D FSE T2 for 2 patients,
Spin echo T1 (SE T1) for 2 patients, and magnetization
prepared rapid acquisition gradient echo T1 (MPRAGE T1)
for all 8 patients. However, for DBS patients the sequences
were prepared so as to run at a low RF power (at SAR <
0.1W/kg). Following earlier reports [9], we have stretched the
refocusing RF pulses by 2–4-fold and reduced the refocusing
angles substantially to attain a whole head RF power level of
0.1W/kg as required per vendor and FDA guidelines [7, 8].
Two readers (EP and RR, both with more than 10 years of
clinical experience) judged the imaging efficacy and clinical
quality of low SAR images.
In addition to the T2 sequences, two other sequences
with spin echo origin (FLAIR T2 and SE T1) were used at
low SAR. The FLAIR sequence was qualitatively assessed for
infection or other indications and was not used for DBS
lead size measurements. Traditionally an inversion-prepared
GRE-based high resolution sequence (MPRAGE) is used
to image gray/white matter and the DBS leads at a high
resolution (typically 1×1×1mm3 isotropic or 1×1×1.5mm3
voxel resolution). Being a gradient echo based method, this
sequence is sensitive to susceptibility and causes a greater
amount of signal loss surrounding themetallic leads.We used
the lead diameter from MPRAGE as the maximum artifact
size that may be acceptable for visualizing adjacent gray or
white matter.
2.3. Image-Based Measurements and Statistical Analysis.
Each of the DBS leads has 4 contacts (1.5 ± 0.1mm in height
and 1.3 ± 0.1mm in diameter, separated by plastic sheaths).
The diameters of one or more contacts in their largest dimen-
sions were measured from magnified MR images as shown
in Figure 1(c). A consistent radiologic intensity window/level
was used for all measurements by a single reader, SS. From
all 8 patients, one estimate of lead diameter per patient
was measured for MPRAGE and was averaged to obtain a
mean 𝐷MPRAGE. From four patients scanned with 2D FSE
T2 sequence, two lead contact estimates per patient were
measured and a total of 8 estimates were averaged to arrive
at a mean 𝐷
2D FSE T2. Four lead contact estimates per patient
for each of two patients with 3D FSE T2 sequences, a total
of 8 estimates, were averaged and a mean 𝐷
3D FSE T2 was
obtained. Finally, four lead contact estimates per patient
for two patients with 2D spin echo T1 results, a total of 8
estimates were averaged and a mean 𝐷
2D SE T1 was obtained.
Six null hypotheseswere drawn to test pairwise equivalence of
means from the four sequences. A nonparametric statistical
test (two-tailed Wilcoxon signed-rank test) was used to
draw conclusions about the mean diameter differences at a
significance level of 0.05 (Table 1).
3. Results
In Figures 1 and 2 typical coronal images from all 4
sequences are shown. In addition the low TE (proton density,
Figure 1(c)) and long TE version of 2D FSE (Figure 1(d)) are
also compared.
Both the readers (EP, RR) concluded that although the
low SAR images are somewhat grainy (due to lower signal-to-
noise) cerebral tissue conspicuity away from as well as adja-
cent to the DBS leads was adequate for radiologic diagnosis
with no noticeable quality difference among spin echo, fast
spin echo, and MPRAGE sequences. As shown in Figure 2,
the FLAIR version of low SAR FSE sequence with long echo
train (80–100) and low refocusing flip angles produces similar
DBS appearance and is useful for imaging of infections and
other complications.
The measured mean lead diameters from the MR images
were as follows:
𝐷MPRAGE = 4.0 ± 0.2mm,
𝐷
2D SE T1 = 2.2 ± 0.1mm,
𝐷
2D FSE T2 = 2.2 ± 0.1mm,
𝐷
3D FSE T2 = 2.1 ± 0.1mm.
The range of lead contact sizes measured from images for
all 8 estimates is listed in Table 1. The mean values represent
the limit attainable for each MR sequence with long echo
train 3D FSE T2 being the best. A 1.3mm standard DBS
lead contact including perhaps a 0.5mm encapsulation layer
is visualized with the least artifactual signal void of 2.1mm
when 3D FSE T2MR sequence is used. Two-dimensional FSE
T2 at long TE (85ms) or SE T1 at short TE (14ms) is also
able to restrict the artifactual blooming of DBS contacts and
encapsulation layers to a total of 2.2mm size signal void while
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Figure 1: Typical coronal MR images, (a) a section from 3D MPRAGE; measured contact diameter (measurement plan is shown in panel
(c) by straight arrows) = 4mm, more than that from (b) a section from 2D SE T1 (2.2mm) or (c) 2D FSE PD (2.3mm) and (d) 2D FSE
T2 (2.3mm) sequences. The location of the lead at left subthalamic nucleus is indirectly estimated as 11-12mm lateral to midline across the
superior-anterior border of the red nucleus (curved arrow, panel (d)).
Table 1: The range of lead contact measurements from various MR sequences.
Lead tip-size measurements 𝐷MPRAGE (mm) 𝐷2D SET1 (mm) 𝐷2DFSET2 (mm) 𝐷3DFSET2 (mm)
1 3.8 2.1 2.3 2.2
2 3.9 2.3 2.1 2.2
3 4.1 2 2.2 2.1
4 4.2 2.2 2 2.1
5 3.9 2.2 2.1 2
6 3.8 2.2 2.1 2
7 3.7 2.1 2.2 2
8 4.3 2.2 2.3 2.1
Mean diameter (mm) 4 ± 0.2 2.2 ± 0.1 2.2 ± 0.1 2.1 ± 0.1
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Figure 2: (a) Coronal 3D long echo train T2 image showing 2.2mm tip diameter (ETL 80, TE 85ms) with visualization of white matter tissue
adequately; (b) and (c) 3D long echo train FLAIRMR signal for an infected DBS lead (arrow showing infection prior to removal (b) and after
removal and treatment (c)). Note the artifactual bright dots in T2 images are not prominently present on FLAIR while the size of the implant
lead is similar to those in T2 images (Figure 1).
Table 2:Wilcoxon signed-rank test results for visualized DBS lead diameters from images using variousMR sequences for DBS patients (C.I.
𝛼 = 0.05).
Test number Null hypotheses mean values (mm) 𝑊,𝑊crit, 𝑃 value Test results
I. 𝐻0: (𝐷MPRAGE − 𝐷2D SET1) = 0 0, 3, 𝑃 ≤ 0.05 Reject𝐻
0
(diameters are significantly different)
4.0 ± 0.2; 2.2 ± 0.1
II. 𝐻0: (𝐷MPRAGE − 𝐷3DFSET2) = 0 0, 3, 𝑃 ≤ 0.05 Reject𝐻
0
(diameters are significantly different)
4.0 ± 0.2; 2.1 ± 0.1
III. 𝐻0: (𝐷MPRAGE − 𝐷2DFSET2) = 0 0, 3, 𝑃 ≤ 0.05 Reject𝐻
0
(diameters are significantly different)
4.0 ± 0.2; 2.2 ± 0.1
IV. 𝐻0: (𝐷2DFSET2 − 𝐷2D SET1) = 0 17, 3, 𝑃 ≤ 0.05 Accept𝐻
0
(diameters are not significantly different)
2.1 ± 0.1; 2.2 ± 0.1
V. 𝐻0: (𝐷3DFSET2 − 𝐷2D SET1) = 0 8, 3, 𝑃 ≤ 0.05 Accept𝐻
0
(diameters are not significantly different)
2.1 ± 0.1; 2.2 ± 0.1
VI. 𝐻0: (𝐷3DFSET2 − 𝐷2DFSET2) = 0 8, 3, 𝑃 ≤ 0.05 Accept𝐻
0
(diameters are not significantly different)
2.1 ± 0.1; 2.2 ± 0.1
short TE (2.3ms) MPRAGE produces the most artifactual
signal loss (4mm on an average). At longer TE values
(T2∗ weighted gradient echo) the artifacts bloom beyond
acceptability for diagnostic use and sequences including
susceptibility weighted imaging (SWI) were not tested on
DBS recipients.
Note that the range of measured diameters is approxi-
mately ±5% of the mean values for all MR sequences. The
standard dimensions of the cylindrical Medtronic 3387/3389
DBS electrode contacts are specified as 1.5 ± 0.1mm height
by 1.3 ± 0.1mm diameter. The electrode encapsulation layer
thickness is 0.5 ± 0.4mm, Haberler et al. [3], Moss et al. [10].
The pairwise statistical mean difference test results are
noted in Table 2 and essentially indicate equivalent blooming
results for all the 2D sequences while suggesting 3D FSE as
the best and 3DMPRAGE as the worst as far as the visualized
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DBS diameters are concerned. The critical limit attainable to
contain the artifactual lead size by any sequence seems to be
approximately 2.1 ± 0.1mm.
4. Discussion
To our knowledge, this is the first MR work that utilizes
very low RF power on refractory Parkinson’s patients to
study the lead contact size in vivo and relates it to the MRI
sequences. The results demonstrate that by lowering echo
time or increasing echo train lengths in fast spin echo the
tissue visualization surrounding the DBS contacts is better
than that obtainable by gradient echo based imaging and it
is possible to achieve a fairly small metallic artifact blooming
from the DBS leads.
In this work, we assumed the electrode surface is perfectly
smooth and ignore any electrode corrosion and surface mod-
ification that may occur as a result of implantation process
or early stages of stimulation treatment. However, analysis of
postmortem or explanted DBS electrodes does not show any
visible surface modification of the metallic contacts or tissue
changes around the active contact and nonstimulated areas
adjacent to the insulated parts as reported by Haberler et al.
[3] and Moss et al. [10].
One may expect that the chosen sequence that performs
better for lead blooming and tissue contrast would use
perfect refocusing RF pulses, long echo train length (ETL),
and short echo time (TE). However, in Figure 1, we notice
that there is a limit, approximately 2.2mm diameter of lead
size, that is reached even with the minimum TE or using
a perfect 180∘ refocusing condition (as in spin echo T1).
The artifact is not reduced when echo train is long, as in
routine 2D FSE T2 with 16 echo trains. The use of a very
long echo train (80–100) as in 3D FSE T2 MR sequence,
even without using perfect 180∘ refocusing conditions as
developed earlier for non-DBS subjects by Sarkar et al. [9],
performs the best among the 4 sequences tested. Note that
these 3D FSE sequences use optimal, much lower refocusing
pulse angles than 180∘. One may speculate, based on these
results, that the current imaging limit to attain minimum
artifactual blooming for MR imaging for a 1.3mm diameter
standard DBS lead contacts surrounded by perhaps a 0.5mm
encapsulation layer is approximately 2.1mm.
Currently, a number of groups use MRI for assessing
DBS lead placement accuracy using high SAR [4] or at
ultralow SAR [11, 12]. Three-dimensional MPRAGE is often
used to assess the lead placement without directly visualizing
the deep brain nuclei that are more conspicuous by FSE
sequences. This work shows that for DBS localization there
are advantages for using 3D acquisition. With 2D imaging
sequences, the slice profiles are less perfect than 3D and often
a slice gap is needed to avoid interslice signal contamination.
Hence 3D sections are expected to performbetter than the 2D
counterparts of similar thickness for lead position verification
and assessment of adjacent tissue viability in case of suspected
complications.
4.1. Limitations of the Study. The tissue edge visualization
depends on the MR signal and image resolution which
directly depend on the magnet field strength, quality of RF
coils, and the clinically feasible imaging time. For safety rea-
sons, Parkinson’s patients with DBS can currently be imaged
only at 1.5 T and with transmit-receive local head coils. Each
of these hardware components operates at approximately half
the performance level compared to those available for routine
patients. Hence refractory PD patients are being imaged at
4-fold lower imaging sensitivity than those imaged at 3 T
with multielement head array coils. In addition, due to RF
power deposition issues, all of our imaging in this work was
done at very low SAR level (0.1W/kg) that also limits, MR
signal-to-noise and extends imaging time. Therefore, with
improved hardware and RF safety limits, our results may
improve and one may be able to use impedance models and
related developments [13] to image substructures around the
implant leads in near future more accurately than obtained
in this work. Finally, our sample size should be extended
to a larger patient population including patients after longer
DBS treatments to image the role of and treatment effects on
encapsulation layer.
5. Conclusions
Conforming to safe RF power limits, this is the first work
reporting MRI sequence dependent artifact size of DBS
leads in refractory Parkinson’s patients and exploring various
sequence limits to minimize the artifactual signal void within
clinically feasible image resolution and hardware limitations
for PD patients. Spin echo and fast spin echo based 2D and
3D FSE sequences provide comparable image blooming of
stimulator leads while 3D FSE produces the smallest artifact
and the gradient echo based 3D MPRAGE produces the
largest.
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